Kymera’s KT-253 is being explored in a variety of liquid and solid tumours. Source: Shutterstock / Juan Gaertner. Clinical-stage biopharma Kymera Therapeutics has announced that
Amgen believes Blincyto, first granted accelerated approval in 2018, has been reinforced as standard of care. Credit: Shutterstock / Chalie Chulapornsiri. Based on a trial
The Chemilogics platform benefits from a wealth of clinical data, and recent advances in genomics, AI and synthetic biology. Source: Shutterstock / metamorworks Life sciences
CSL’s Hemgenix uses an engineered adeno-associated virus (AAV) to make the body produce blood clotting proteins. Source: Shutterstock / Kateryna Kon. CSL announced the first
Lilly is hoping to continue its foray into immunology. Source: Shutterstock / Jonathan Weiss Looking to shore up its immunology offering, Eli Lilly is set
Immune globulin treatments are the only available MMN therapies – but ARGX-117 could change that. Source: Shutterstock / Kateryna Kon. Netherlands-based immunology company Argenx has
F2G’s Olorofim is intended to treat rare fungal infections such as azole-resistant aspergillosis, scedosporiosis and lomentosporiosis Source: Shutterstock / Kateryna Kon. UK-based biotech F2G was
The company will develop Lucis’ liquid pipeline products. Source: Shutterstock / Matveev Aleksandr. Oral liquid medicine manufacturer Rosemont Pharmaceuticals has announced the acquisition of Lucis
Tessa Therapeutics’ TT11X is a highly specialised CAR-T therapy that can kill cancer cells. Source: Shutterstock / SciePro Clinical-stage cell therapy company Tessa Therapeutics have
MSD will now work with the FDA to update Keytruda’s label. Source: Shutterstock / Atmosphere1. Merck (MSD) has announced updated results with Keytruda (pembrolizumab) in